The extracellular matrix in breast cancer predicts prognosis through composition, splicing, and crosslinking 
Introduction
When metastatic breast cancer cells are mixed with murine mammary epithelial cells and injected into the mammary fat pad, one would expect to observe frank tumors [1] . However, instead of tumors, these cancerous cells incorporate into histologically normal ductal structures, respond appropriately to hormones, and even secrete milk proteins [2] . Furthermore, breast epithelial cells with surprisingly abnormal genomes can be found in histologically normal human breast ducts [3] [4] [5] .
These studies, and many others, show that the correct context can induce non-malignant behavior, whereas, the abnormal environment in tumors can induce progressive genomic instability and tumorigenesis even in non-malignant cells, both in vitro and in animal models [6] [7] [8] . Recent work has linked the ECM in tumors to dormancy [9] , resistance to chemotherapy or radiation [10] [11] [12] , metastasis and metastasis tropism [13] again demonstrating the importance of understanding cell-ECM interactions. It has become apparent from both in vitro and clinical work that the ECM signals to cells through both biochemical and physical means with complex interactions between ECM composition, splicing, microstructure, and biomechanics. This work gives a survey of the alterations to ECM observed in the progression from healthy breast to breast cancer with special attention to biomechanics. We will focus on data from the breast and breast cancer, as cell-matrix interactions have been studied extensively for this organ system and cell culture models of breast development and breast cancer show clear clinical relevance [14, 15] .
ECM in the healthy breast suppresses tumorigenesis

The basement membrane in the normal breast is a tumor suppressor
The epithelial structures in the breast originate at the nipple, form a branching set of ducts, and end in terminal ductal lobular units, where milk is synthesized. Breast ducts and lobules are bilayered structures: the inner ring of luminal epithelial cells, which secrete milk during lactation, is surrounded by a ring of myoepithelial cells, which are contractile cells with the ability to secrete and organize ECM proteins. Subtending both these layers of cells is a highly specialized layer of extracellular matrix proteins termed the basement membrane (BM). Myoepithelial cells are lost with malignant progression [16] [17] [18] and are believed to play an important tumor suppressive role in the healthy breast due to their ability to secrete the specialized extracellular matrix proteins of the BM [16, 19] . Myoepithelial cells surrounding tumors show a shift in ECM protein secretion, losing expression of tumor-suppressive laminins and increasing expression of collagens [16, 20] .
The basement membrane (BM), a complex, crosslinked layered structure of multiple laminins, collagen IV and other collagens, proteoglycans including perlecan/heparin sulfate proteoglycan nidogen/entactin, and others. Loss of an intact basement membrane is a key stage in malignant progression with high predictive value for prognosis [21] , and animal models show that destruction of the BM results in genetic instability and tumorigenesis [7, 8] .The innermost layer of the basement membrane, at the epithelial cell surface, is a network of laminins [22, 23] . In the presence of cell surface ECM receptors, such as dystroglycan, laminin-111 can polymerize into a soft, cohesive network [23, 24] , which then induces formation of a more structurally stable collagen IV network subtending the Ln-111 network [25] , which epithelial cells do not typically contact. These independent networks are then linked by proteins such as fibronectin and nidogens [26] , permitting formation of a cohesive mat of proteins.
Among BM proteins, laminin-111 is absolutely necessary for epithelial specific functions in 3D culture assays, including formation of polarity in human breast epithelial cells [16] , and induction of milk protein expression (including beta-casein) in murine mammary gland epithelial cells [27] . Furthermore, tumor reversion, or induction of a quiescent phenotype in malignant cells requires laminin and induction of normal cell-ECM signaling [16, 28] . Laminin-111/Ln-1 has three head domains which can crosslink into a soft cohesive 3D network, whereas other laminin isoforms with truncated head domains, such as laminin-332/Ln-5, laminin-511/Ln-10 or laminin-521/Ln-11, cannot form a network [22, 29] , and do not support normal epithelial cell function in vitro, despite the fact that all these isoforms present similar tail domains to cells [16] . Furthermore, some evidence suggests that laminin-332, or collagen IV may support tumor invasion or aggressiveness [30] [31] [32] .
Both the biomechanics and composition of this laminin network regulate epithelial function: artificially stiffening the laminin network induces epithelial cells to enter an invasive phenotype due to disrupted clustering of β-4 integrin into hemidesmosomes [33] and increased β1 integrin signaling [34, 35] . Increasing the density of laminin sites can overcome increased matrix stiffness [33] , showing that cells integrate multiple aspects of ECM.
Given the small dimensions of the breast BM (30-50 nm in the human breast [36] ), the biomechanical properties of the mammary gland basement membrane itself have never been experimentally determined (though breast stromal tissue has a modulus of 200-400 Pa [35, 37] ). The BM subtending the retina (which has a similar laminin-rich composition) has a modulus between 1 and 4 MPa, with a difference in matrix biomechanics between its two faces [38] , suggesting that despite the thinness of this structure it specializes into sides.
Stroma
Surrounding the ducts and lobules of the glandular epithelium is the breast stroma, comprised of adipocytes, fibroblasts, and capillaries embedded in a different mix of ECM [39] . The stroma contains blood vessels, adipocytes and fibroblasts embedded in abundant collagen I, chondroitin sulfate and fibronectin [40] (note that the blood vessels have their own laminin-rich BM [41] ). Despite their separation by the BM, stroma communicates with epithelia, and stromal changes are observed even in the early stages of malignancy [42] . Stromal ECM plays a major role in tumorigenesis: genetic work from both animal models [8, 43] and the clinic [44, 45] show that stromal gene expression can alter probablility of developing breast cancer. Importantly, gene expression patterns of normal stroma adjacent to breast cancers shows a different gene expression pattern from normal tissue from unaffected patients [46] . Changes in stromal ECM are observed even in ductal carcinoma in situ (DCIS), where carcinoma cells are confined within an intact basement membrane, including increased deposition of versican [47] , loss of decorin [48] , and altered expression of Col11A1 [46, 49] .
Direct contact between stroma and non-malignant epithelia is not observed except during involution [50] . Breast cancers arising during pregnancy and involution tend to be highly aggressive and metastatic [51] , suggesting that the collagen-1 rich stromal ECM, along with inflammatory environment observed in lactation and involution, could be pro-tumorigenic [52] . Supporting this, mouse models of BM destruction or stromal collagen I overexpression, which would tend to increase exposure of epithelia to stromal ECM, show increased tumorigenesis [8, 53] . Furthermore, nonmalignant epithelial cells exposed to increased density of stromallike collagen I and associated increases in ECM biomechanics undergo transition between formation of normal structures and loss of cell structure and increased growth [35] . The microarchitecture of the fibrilar collagen network (typically collagen I) in the stroma is believed to play a major role in specifying both risk of BC and the stiffness of the stromal ECM [37, 50, 54, 55] , suggesting that stiff stroma could encourage tumor initiation or progression. Depending on species, age and testing method, breast interstitial ECM has been measured to have a modulus of 167731 Pa [35] , 0.4 kPa [37] and 1.13 70.78 kPa [55] , and the risk of developing BC has been linked to increases in total breast stiffness both clinically [54] .
ECM in tumors
Altered ECM and altered cell response
In breast cancers, high levels of fibronectin and its splice variants, crosslinked collagen I, and tenascin-C are associated with poorer survival or time to progression for breast cancer patients, whereas high levels of laminins, high molecular weight hyaluronic acid, heparins, versican, lumican or decorin correlate with better outcomes (summarized in Table 1 ). While biological mechanisms for some of these links between ECM signatures and prognosis, many open questions remain. 15 BC lumican was highly abundant relative to decorin, while biglycan and fibromodulin are only detected occasionally [143] lumican mRNA was increased in tumors while decorin mRNA was decreased in neoplastic relative to adjacent normal stroma along with an increase in lumican, but not decorin IHC for decorin 98 samples IBC and 22 were from patients with DCIS Decorin was observed in stroma but not epithelia. Average decorin expression decreased from normal to DCIS to IDC [48] IHC for Syndecan 1,4, and Glypican 1 207 BC Glypican-1 detected in a small sample of BC [144] Higher level of Syndecan 1 and -4 predicted higher
Breast cancer subtypes
Some of the link between ECM and prognosis may relate to the phenotype or subtypes which associate with certain ECM configurations and the known differences in prognosis associated with these subtypes. Breast cancer is not a single disease [38] : breast cancer prognosis varies with expression of key hormone receptors: estrogen receptor (ER), progesterone receptor (PR) and her2/neu/ ERbB2 (Her2) [56] histologic grade [57] , and presence of metastasis. Recent evidence suggests that the microenvironment in these tumors is different [58, 59] .
For example, triple negative tumors which display mutant p53, typically have very poor survival [60] . These tumors tend to show complete loss of laminin and high levels of vascularization, which may explain some of the linkage between this form of ECM and poor outcome [61] . Stiff tumors, measured with ultrasound elastography, tend to be the most aggressive types, including triple negative or Her2 þ tumors [62] . High levels of hyaluronic acid appears linked to HER2 þ cancers, which tend to be more aggressive [61] . Patients with lumican and decorin polymorphisms appear to develop more ER þ cancers [45] , which usually have better prognosis.
Similarly, some ECM signatures may only predict prognosis in certain subtypes: for example, SPARC mRNA level, though highest in luminal A tumors, predicts prognosis in basal and Her2 þ tumors, but not in luminal types [63] , whereas fibronectin, highest in TNBC/basal or Her2þ tumors, has the highest prognostic value in hormone positive cancers [64] . Alternatively, in vitro work has suggested that ECM can alter expression subtype markers, further confounding the link to prognosis [65, 66] As a result, studies with different clinical samples can show very different results, and caution is needed in interpreting findings.
ECM protein splicing/structure changes
An estimated 75% of proteins have alternative splice forms [67] , and changes to the spliceosome are observed with the progression from normalcy to malignancy [67, 68] . Unsurprisingly, the ECM proteins with alternative splice forms are often observed to undergo isotype switching during development of cancer, though microenvironmental factors can normalize splicing in malignant cells [69] . The ED-A and ED-B fibronectin splice forms, i.e. the oncofetal splice variants or proangiogenic isoforms [70, 71] , display the integrin binding RGD domain differently, [72] , and may show different assembly into fibrils [73] . Notably these variants are not found in soluble plasma fibrinogen, suggesting that these forms are more likely to polymerize [74] . Malignant cells express much higher levels of ED-A fibronectin and its receptor, α5β1 integrin, both of which have been linked to radiation resistance [75] . Likewise, tenascin-c also has multiple alternative splice forms, which are not observed in normal adult breast tissue [76] . In both patient samples and cell culture models, these splice forms have been linked to invasiveness, potentially through MMP-based mechanisms [76, 77] .
Furthermore, the abberant ECM in tumors can alter fibronectin splicing even in non-malignant cells, whereas normalization of cell-matrix interactions in malignant cells normalizes fibronectin splicing [75] . Increased tissue stiffness appears to induce global changes in splicing, driving increased expression of ED-B fibronectin [78] . High levels of glucose in media likewise appear to alter expression of ED-B fibronectin splicing along with increasing total levels of fibronectin [79] .
Microstructure, biomechanics and crosslinking
Among ECM components, fibrillar collagen I is believed to be the major determinant of breast and breast cancer stiffness [53] , and has been proposed as a link between increased mammographic breast density (a well-known breast cancer risk factor) and increased risk of breast cancer [80] . Mouse models of increased collagen deposition confirm that increased collagen density likewise regulates breast cancer susceptibility [53] . Furthermore, increased expression of fibrillar collagens is observed in invasive breast cancers compared to normal or to DCIS [81, 82] While collagen I is only one of many breast ECM components with cell regulatory effects, it represents the best characterized model for studying microstructure and its effects on cells.
The diverse microarchitectures of fibrillar collagen and the range of resulting biomechanics can result in very different microenvironments despite equivalent levels of collagen [83] [84] [85] , which potentially explains the weak clinical link between collagen I and prognosis in older studies [86, 87] . It remains difficult to decouple the effects of fiber diameter, pore size and biomechanics, but it appears that all three act on cells (reviewed in [88] ). For example, crosslinking and crosslinking density each affect cell invasion, with a significant interaction, such that crosslinking loose ECM environments increased invasiveness, whereas crosslinking dense ECM decreased invasiveness [89] .
Due to altered ECM microstructure and crosslinking, the increased stiffness of breast tumors is so different from the surrounding tissue that manual palpation remains an important diagnostic [90] . Tumor stiffness, assessed with ultrasound elastography or atomic force microscopy appears to increase with increasing grade [91] and predicts poorer prognosis [92] . SPARC/ OSTEONECTIN Microarray for 7 genes which correlate with SPARC 1729 systemically untreated patients from previously published datasets SPARC tends to be highest in luminal-A type, followed by luminal-B followed by basal [63] High SPARC predicts worse survival in HER2 þ, and basal cancers Furthermore, successful chemotherapy decreases tumor stiffness whereas stiffening is observed in chemotherapy-resistant tumors stiffen after treatment [93] . In contrast, softer collagen I rich matrices appear to reduce breast cancer risk and progression. Parity appears to increase collagen I deposition, but in an unorganized, uncrosslinked form, resulting in softer ECM and reduced risk of breast cancers [83] . Collagen III disrupts formation of dense, organized collagen I networks, resulting in softer ECM [94] . Loss of collagen III in mouse models is associated with tumor aggressiveness [94] , though Col III is often observed to be overexpressed with increasing tumor grade [20, 81, 82, 95] . Furthermore, reductions in collagen I density via TGFβ blockade likewise suggest that altering collagen network structure is a potential therapeutic target [96] .
A dense network of collagen fibers perpendicular to tumor border predicts invasiveness and poorer overall survival [97, 98] . In mesenchymal cells, organization of fibriliar matrices is the major determinant of migration patterns, such that cell migration persistence tends to be highest in aligned matrices [97, [99] [100] [101] . Both non-malignant and malignant epithelial cells respond to the biomechanics of their surrounding matrix [35] , through multiple mechanisms [6, 33, 35, 102] . Lysyl oxidases, by crosslinking collagens increase tumor stiffness [103] , and predict prognosis [86] .
ECM and chemotherapy
Resistance to chemotherapy has been linked to features of ECM through several avenues. In ER-breast cancers, gene expression patterns typical of reactive stroma predicted resistance to chemotherapy, though no link was found between this signature and outcome in untreated patients [10] . Similarly, tumor stiffness measured with ultrasound elastography predicted residual tumor burden after chemotherapy [104] [105] [106] . Interestingly, clinical response to chemotherapy involved a softening of the tumor site, whereas resistant tumors became stiffer after treatment [93] . Among elements of reactive stroma, increased ECM stiffness predicted resistance in vitro to the broad spectrum tyrosine kinase inhibitor sorafenib [107] .
Integrins and many of the tyrosine kinase receptors (such as EGFR [108] , ErbB2, VEGFRs, HFGRs, etc.) are known to cross regulate each other in stiff environments, potentiating both integrin signaling and often increasing receptor potency [107, [109] [110] [111] . Her2 is acutely regulated by FAK, such that ECM stiffening is a powerful regulator of Her2 and of Her2 resistance [65, 110, 112] . Adhesion to laminin-332 through a6b4 has also been linked to trastuzumab resistance through the transmembrane protein CD151 [113] . We would argue that further work is urgently needed to understand the role of ECM in mediating chemotherapy resistance.
Conclusions how does ECM remodeling keep healthy tissues healthy and how did tumors get that way?
The natural history of breast cancer still remains poorly understood, and may differ by cell of origin [114, 115] , subtype or yet unknown factors. However, a preponderance of evidence now shows that the insoluble proteins comprising the extracellular matrix (ECM) can suppress tumor development and progression, whereas the abnormal ECM in tumors can promote progression of cancers and resistance to treatment. The diverse mechanisms by which cells sense and respond to their surrounding ECM represent an attractive target for new therapeutics for cancers [116] . However, the dramatic failure in clinical trials of one such class of treatment, namely MMP inhibitors [117] highlights the need for improved models and improved understanding of cell-ECM 
